Genetic Modulation of Antigen Presentation

  • Mary Lynne Hedley


Specific immune responses, whether they involve up or down regulation, begin with the presentation of peptides by major histocompatibility complex (MHC) class I or II molecules to T cells. Subsequent to this initial recognition event, the T cell may exhibit one of several different responses. These can be regulated by accessory molecules on the antigen presenting cell (APC), cytokines, or the location in which the presentation event occurred.


Genetic Modulation Human Papilloma Virus Transporter Associate With Antigen Processing Direct Gene Transfer Genetic Immunization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Madden D. The three-dimensional structure of peptide-MHC complexes. In: Paul WE, Fathman CG, Metzger H, eds. Annual Review of Immunology. vol 13. Palo Alto: Annual Reviews Inc., 1995: 587–622.Google Scholar
  2. 2.
    Engelhard V. Structure of peptides associated with class I and class II MHC molecules. In: Paul WE, Fathman CG, Metzger H, eds. Annual Review of Immunology. vol 12. Palo Alto: Annual Reviews, Inc., 1994: 181–207.Google Scholar
  3. 3.
    Rammensee H-G, Falk K, Rotzschke O. Peptides naturally presented by MHC class I molecules. In: Paul WE, Fathman CG, Metzger H, eds. Annual Review of Immunology. vol 11. Palo Alto: Annual Reviews, Inc., 1993: 213–44.Google Scholar
  4. 4.
    Sette A, ed Naturally Processed Peptides, Chemical Immunology vol 57. Basel: Karger 1993.Google Scholar
  5. 5.
    Wang C-Y, Huang L. pH-sensitive immunoliposomes mediate target-cellspecific delivery and controlled expression of a foreign gene in mouse. Proc Natl Acad Sci USA 1987; 84: 7851–55.CrossRefGoogle Scholar
  6. 6.
    Nabel EG, Plautz G, Nabel GJ. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 1990; 249: 1285–88.CrossRefGoogle Scholar
  7. 7.
    Wolff JA, Malone RW, Williams P et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465–68.CrossRefGoogle Scholar
  8. 8.
    Ning Y-S, Burkholder J, Roberts B et al. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci USA 1990; 87: 9568–72.CrossRefGoogle Scholar
  9. 9.
    Jonjic S, Del Val M, Keil GM et al. A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection. J Virol 1988; 62: 1653–58.Google Scholar
  10. 10.
    Klavinskis LS, Whitton JL, Oldstone MBA. Molecularly engineered vaccine which expresses an immunodominant T cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus protection. J Virol 1989; 63: 4311–16.Google Scholar
  11. 11.
    Hany M, Oehen S, Schulz M et al. Anti-viral protection and prevention of lymphocytic choriomeningitis or of the local footpad swelling reaction in mice by immunization with vaccinia-recombinant virus expressing LCMV-WE nucleoprotein or glycoprotein. Eur J Immunol 1989; 19: 417–24.CrossRefGoogle Scholar
  12. 12.
    Andrew ME, Coupar BEH. Efficacy of influenza haemagluttinin and nucleoprotein as protective antigens against influenza virus infection in mice. Scand J Immunol 1988; 28: 81–85.CrossRefGoogle Scholar
  13. 13.
    Webster RG, Kawaoka Y, Taylor J et al. Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine 1991; 9: 303–08.CrossRefGoogle Scholar
  14. 14.
    King AMQ, Stott EJ, Langer SJ et al. Recombinant Vaccinia viruses carrying the N gene of human respiratory syncytial virus: Studies of gene expression in cell culture and immune respones in mice. J Virol 1987; 61: 2885–90.Google Scholar
  15. 15.
    Lawson CM, Bennink JR, Restifo NP et al. Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge. J Virol 1994; 68: 3505–11.Google Scholar
  16. 16.
    Williams RS, Johnston SA, Riedy M et al. Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles. Proc Natl Acad Sci USA 1991; 88: 2726–30.CrossRefGoogle Scholar
  17. 17.
    Wolff JA, Ludtke JL, Acsadi G et al. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Gen 1992; 1: 363–69.CrossRefGoogle Scholar
  18. 18.
    Tang D, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356: 152–54.CrossRefGoogle Scholar
  19. 19.
    Robinson HL, Hunt LA, Webster RG. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 1993; 11: 957–60.CrossRefGoogle Scholar
  20. 20.
    Fynan EF, Webster RG, Fuller DH et al. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 1993; 90: 11478–82.CrossRefGoogle Scholar
  21. 21.
    Ulmer JB, Donnelly, JJ, Parker, SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745–49.CrossRefGoogle Scholar
  22. 22.
    Donnelly JJ, Ulmer JB, Liu MA. Immunization with DNA. J Immunol Methods 1994; 176: 145–52.CrossRefGoogle Scholar
  23. 23.
    Sedegah M, Hedstrom R, Hobart P et al. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci USA 1994; 91: 9866–70.CrossRefGoogle Scholar
  24. 24.
    Hill A, Jugovic P, York I et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995; 375: 411–15.CrossRefGoogle Scholar
  25. 25.
    Fruh K, Ahn K, Djaballah H et al. A viral inhibitor of peptide transporters for antigen presentation. Nature 1995; 375: 415–18.CrossRefGoogle Scholar
  26. 26.
    Levitskaya J, Coram M, Levitsky V et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995; 375: 685–88.CrossRefGoogle Scholar
  27. 27.
    Phelan A, Carmo-Fonesca M, McLauchlan J et al. A herpes simplex virus type 1 immediate-early gene product, IE63, regulates small nuclear ribonucleoprotein distribution. Proc Natl Acad Sci USA 1993; 90: 9056–60.CrossRefGoogle Scholar
  28. 28.
    Davis HL, Whalen RG, Demeneix BA. Direct gene transfer into skeletal muscle in vivo: Factors affecting efficiency of transfer and stability of expression. Hum Gene Ther 1993; 4: 151–59.CrossRefGoogle Scholar
  29. 29.
    Alexander J, Sidney J, Southwood S et al. Development of high potency univerisal DR-restricted helper epitopes by modification of high-affinity DR-blocking peptides. Immunity 1994; 1: 751–61.CrossRefGoogle Scholar
  30. 30.
    Whitton JL, Oldstone MBA. Class I MHC can present an endogenous peptide to cytotoxic T lymphocytes. J Exp Med 1989; 170: 1033–38.CrossRefGoogle Scholar
  31. 31.
    Sweetser MT, Braciale VL, Braciale TJ. Class I MHC-restricted recognition of cells expressing a gene encoding a 41 amino acid product of the influenza hemagglutinin. J Immunol 1988; 141: 3324–28.Google Scholar
  32. 32.
    Gould K, Cossins J, Bastin J et al. A 15 amino acid fragment of influenza nucleoprotein synthesized in the cytoplasm is presented to class-I restricted cytotoxic T lymphocytes. J Exp Med 1989; 170: 1051–56.CrossRefGoogle Scholar
  33. 33.
    Klavinskis LS, Whitton JL, Joly E et al. Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope. Virology 1990; 178: 393–400.CrossRefGoogle Scholar
  34. 34.
    Eisenlohr LC, Bacik I, Bennink JR et al. Expression of a membrane protease enhances presentation of endogenous antigens to MHC class I-restricted T lymphocytes. Cell 1992; 71: 963–72.CrossRefGoogle Scholar
  35. 35.
    Oldstone MBA, Tishon A, Eddelston M et al. Vaccination to prevent persistent viral infection. J Virol 1993; 67: 4372–78.Google Scholar
  36. 36.
    Bergmann CC, Tong L, Cua RV et al. Cytotoxic T cell repertoire selection. J Immunol 1994; 152: 5603–12.Google Scholar
  37. 37.
    Restifo NP, Bacik I, Irvine KR et al. Antigen processing in vivo and the elicitation of primary CTL responses. J Immunol 1995; 154: 4414–22.Google Scholar
  38. 38.
    Anderson K, Cresswell P, Gammon M et al. Endogenously synthesized peptide with an endoplasmic retention signal sensitizes antigen processing mutant cells to class I-restricted cell mediated lysis. J Exp Med 1991; 174: 489–92.CrossRefGoogle Scholar
  39. 39.
    Zweerink HJ, Gammon MC, Utz U et al. Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. J Immunol 1993; 150: 1763–71.Google Scholar
  40. 40.
    Bacik I, Cox JH, Anderson R et al. TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino-but not carboxyl-terminus of the peptide. J Immunol 1994; 152: 381–87.Google Scholar
  41. 41.
    Nothwehr SF, Gordon JI. Targeting of proteins into the eukaryotic secretory pathway: signal peptide structure/function relationships. Bioessays 1990; 12: 479–84.CrossRefGoogle Scholar
  42. 42.
    von Heijne G. Protein targeting signals. Curr Op Cell Biol 1990; 2: 604–08.CrossRefGoogle Scholar
  43. 43.
    Pugsley AP. Translocation of proteins with signal sequences across membranes. Curr Op Cell Biol 1990; 2: 609–16.CrossRefGoogle Scholar
  44. 44.
    Rottier PJM, Florkiewicz RZ, Shaw AS et al. An internalized amino-terminal signal sequence retains full activity in vivo but not in vitro. J Biol Chem 1987; 262: 8889–95.Google Scholar
  45. 45.
    Muller G, Zimmerman R. Import of honeybee prepormelittin into the endoplasmic reticulum: structural basis for independence of SRP and docking protein. Embo J 1987; 6: 2099–107.Google Scholar
  46. 46.
    Schlenstedt G, Zimmerman R. Import of frog prepropeptide GLa into microsomes requires ATP but does not involve docking protein or ribosomes. Embo J 1987; 6: 699–703.Google Scholar
  47. 47.
    Gammon MC, Bednarek MA, Biddison WE et al. Endogenous loading of HLA-A2 molecules with an analog of the influenza virus matrix protein-derived peptide and its inhibition by an exogenous peptide antagonist. J Immunol 1992; 148: 7–12.Google Scholar
  48. 48.
    Bednarek MA, Sauma SY, Gammon MC et al. The minimum peptide epitope from the influenza virus matrix protein. J Immunol 1991; 147: 4047–53.Google Scholar
  49. 49.
    Germain RN, Margulies DH The biochemistry and cell biology of antigen processing and presentation. In: Paul WE, Fathman CG, Metzger H, eds. Annual Review of Immunology. vol 11. Palo Alto: Annual Reviews, Inc., 1993: 403–50.Google Scholar
  50. 50.
    Chicz RM, Urban RG. Analysis of MHC-presented peptides:applications in autoimmunity and vaccine development. Immunol Today 1994; 15: 155–60.CrossRefGoogle Scholar
  51. 51.
    Slingluff Jr. CL, Hunt DF, Engelhard VH. Direct analysis of tumor-associated peptide antigens. Curr Opin Immunol 1994; 6: 733–40.CrossRefGoogle Scholar
  52. 52.
    Oldstone MBA, Tishon A, Geckeler R et al. A common antiviral cytotoxic T lymphocyte epitope for diverse major histocompatibility complex haplotypes:Implications for vaccination. Proc Natl Acad Sci USA 1992; 89: 2752–55.CrossRefGoogle Scholar
  53. 53.
    Nixon DF, McMichael AJ. Cytotoxic T cell recognition of HIV proteins and peptides. AIDS 1991; 5: 1049–53.Google Scholar
  54. 54.
    Koenig S, Fuerst TR, Wood LV et al. Mapping the fine specificity of a cytotoxic T cell response to HIV-1 nef protein. J Immunol 1990; 145: 127–35.Google Scholar
  55. 55.
    Culmann B, Gomard E, Kieny M-P et al. Six epitopes reacting with human cytotoxic CD8’ T cells in the central region of the HIV-1 NEF protein. J Immunol 1991; 146: 1560–65.Google Scholar
  56. 56.
    Imanishi T, Akaza T, Kimura A et al. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: Tsuji K, Aizawa M, Sasazuki T, eds. HLA 1991, Proceedings of the eleventh international histocompatibility workshop and conference. vol 1. Tokyo: Oxford University Press, 1992: 1066–77.Google Scholar
  57. 57.
    Thomson SA, Khana R, Gardner J et al. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to cytotoxic T cells: Implications for vaccine design. Proc Natl Acad Sci USA 1995; 92: 5845–49.CrossRefGoogle Scholar
  58. 58.
    Boon T, Cerottini J-C, Van dne Eynde B. Tumor antigens recognized by T lymphocytes. In: Paul WE, Fathman CG, Metzger H, eds. Annual Review of Immunology. vol 12. Palo Alto: Annual Reviews Inc., 1994: 337–65.Google Scholar
  59. 59.
    Slingluff CL, Cox AL, Henderson RA et al. Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lympphocytes is mediated by at least six shared peptide epitopes. J Immunol 1993; 150: 2955–63.Google Scholar
  60. 60.
    Storkus WJ, Zeh HJ, Maeurer MJ et al. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol 1993; 151: 3719–27.Google Scholar
  61. 61.
    Cox AL, Skipper J, Chen Y et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994; 264: 716–19.CrossRefGoogle Scholar
  62. 62.
    Mandelboim O, Berke G, Fridkin M et al. CTL induction by a tumor associated antigen octapeptide derived from a murine lung carcinoma. Nature 1994; 369: 67–71.CrossRefGoogle Scholar
  63. 63.
    Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity. Immunol Today 1993; 14: 483–86.CrossRefGoogle Scholar
  64. 64.
    Conry RM, LoBuglio AF, Kantor J et al. Immune response to a carcinoembryonic antigen polynucleotide vaccine. Cancer Research 1994; 54: 1164–68.Google Scholar
  65. 65.
    Pardoll DM. A new look for the 1990’s. Nature 1994; 369: 357–58.CrossRefGoogle Scholar
  66. 66.
    Nabel GJ, Nabel EG, Yang Z-y et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90: 11307–11.CrossRefGoogle Scholar
  67. 67.
    Wauben MH, Kozhich A, Joosten I et al. Inhibition of entire myelin basic protein-induced experimental autoimmune encephalomyelitis in Lewis rats by major histocompatibility complex class II-binding competitor peptides. Eur J Immunol 1994; 24: 1053–60.CrossRefGoogle Scholar
  68. 68.
    Ishioka GY, Adorini L, Guery J-C et al. Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. J Immunol 1994; 152: 4310–19.Google Scholar
  69. 69.
    Urban RG, Chicz RM, Strominger JL. Selective release of some invariant chain-derived peptides from HLA-DR1 molecules at endosomal pH. J Exp Med 1994; 180: 751–55.CrossRefGoogle Scholar
  70. 70.
    Merino R, Iwamoto M, Fossati L et al. Prevention of systemic lupus erythematosus in autoimmune BXSB mice by a transgene encoding I-Ea chain. J Exp Med 1993; 178: 1189–97.CrossRefGoogle Scholar
  71. 71.
    Chicz RM, Urban RG, Gorga JC et al. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993; 178: 27–47.CrossRefGoogle Scholar
  72. 72.
    Bijlmakers M-J J. E, Benaroch P, Ploegh HL. Assembly of HLA-DR1 molecules translated in vitro: binding of peptide in the endoplasmic reticulum precluded assoication with invariant chain. Embo J 1994; 13: 2699–707.Google Scholar
  73. 73.
    Hedley ML, Urban RG, Strominger JL. Assembly and peptide binding of major histocompatibility complex class II heterodimers in an in vitro translation system. Proc Natl Acad Sci USA 1994; 91: 10479–83.CrossRefGoogle Scholar
  74. 74.
    Peters PJ, Neefles JJ, Oorschot V et al. Segregation of MHC class II molecules from MHC class I molecules in the Golgi complex for transport to lysosomal compartments. Nature 1991; 349: 669–76.CrossRefGoogle Scholar
  75. 75.
    Harding CV, Geuze HJ. Immunogenic peptides bind to class II MHC molecules in an early lysosomal compartment. J Immunol 1993; 151: 3988–98.Google Scholar
  76. 76.
    Amigorena S, Drake JR, Webster P et al. Transient accumulation of new class II molecules in a novel endocytic compartment in B lymphocytes. Nature 1994; 369: 113–20.CrossRefGoogle Scholar
  77. 77.
    Tulp A, Verwood D, Dobberstein B et al. Isolation and characterization of the intracellular MHC class II compartment. Nature 1994; 369: 120–26.CrossRefGoogle Scholar
  78. 78.
    West MA, Lucocq JM, Watts C. Antigen processing and class II MHC peptide loading compartments in human B-lymphoblastoid cells. Nature 1994; 369: 147–51.CrossRefGoogle Scholar
  79. 79.
    Bodmer H, Viville S, Benoist C et al. Diversity of endogenous epitopes bound to MHC class II molecules limited by invariant chain. Science 1994; 263: 1284–86.CrossRefGoogle Scholar
  80. 80.
    Germain RN, Rinker AG. Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes surface expression of occupied molecules. Nature 1993; 363: 725–28.CrossRefGoogle Scholar
  81. 81.
    Reid PA, Watts C. Constitutive endocytosis and recycling of major histocompatibility class II glycoproteins in human B-lymphoblastoid cells. Immunol 1992; 77: 539–42.Google Scholar
  82. 82.
    Simonsen A, Momburg F, Drexler J et al. Intracellular distribution of the MHC class II molecules and the associated invariant chain (Ii) in different cell lines. Intern Immunol 1993; 5: 903–17.CrossRefGoogle Scholar
  83. 83.
    Pinet V, Vergelli M, Martin R et al. Antigen presentation mediated by recycling of surface HLA-DR molecules. Nature 1995; 375: 603–06.CrossRefGoogle Scholar
  84. 84.
    Sanderson S, Frauwirth K, Shastri N. Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins. Proc Natl Acad Sci USA 1995; 92: 7217–21.CrossRefGoogle Scholar
  85. 85.
    Martinon F, Krishnan S, Lenzen G et al. Induction of virus-specific cytotxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 1993; 23: 1719–22.CrossRefGoogle Scholar
  86. 86.
    Plautz GE, Yang Z-Y, Wu B-Y et al. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 1993; 90: 4645–49.CrossRefGoogle Scholar
  87. 87.
    Nabel EG, Plautz G, Nabel GJ. Transduction of a foreign histocompatibility gene into the arterial wall induces vasculitis. Proc Natl Acad Sci USA 1992; 89: 5157–61.CrossRefGoogle Scholar
  88. 88.
    Gref R, Minamitake Y, Peracchia MT et al. Biodegradable long-circulating polymeric nanospheres. Science 1994; 263: 1600–03.CrossRefGoogle Scholar
  89. 89.
    Kensil CR, Patel U, Lennick M et al. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria molina cortex. J Immunol 1991; 146: 431–37.Google Scholar
  90. 90.
    Newman MJ, Wu J-Y, Gardner BH et al. Saponin adjuvant induction of ovalbumin-specific CD8’ cytotoxic T lymphocyte responses. J Immunol 1992; 148: 2357–62.Google Scholar
  91. 91.
    Weiner H, Friedman A, Miller A et al. Oral Tolerance: Immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. In: Paul WE, Fathman CG, Metzger H, eds. Annual Review of Immunology. vol 12. Palo Alto: Annual Reviews Inc., 1994: 809–37.Google Scholar
  92. 92.
    Stribling R, Brunette L, Liggitt D et al. Aerosol gene delivery in vitro. Proc Natl Acad Sci USA 1992; 89: 11277–81.CrossRefGoogle Scholar

Copyright information

© R.G. Landes Company 1996

Authors and Affiliations

  • Mary Lynne Hedley

There are no affiliations available

Personalised recommendations